Press Releases April 28, 2026 04:05 PM

SuRo Capital Corp. to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

SuRo Capital Corp. Announces Q1 2026 Financial Results Release and Investor Conference Call on May 5, 2026

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
SSSS

SuRo Capital Corp., a publicly traded investment fund focused on venture-backed high-growth private companies, will report its Q1 2026 financial results after market close on May 5, 2026. The company will host a conference call and webcast to discuss the results with investors, providing insights into its portfolio which includes AI infrastructure, emerging consumer brands, and software solutions.

SuRo Capital Corp. to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
SSSS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SuRo Capital Corp. will release Q1 2026 financial results on May 5, 2026, followed by an investor conference call and webcast.
  • The firm invests in high-growth, venture-backed private companies spanning sectors like AI infrastructure, consumer brands, and enterprise software.
  • SuRo Capital aims to provide public market access to innovative private companies before they go public.

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- SuRo Capital Corp. (“SuRo Capital”) (Nasdaq: SSSS) today announced that it will report its financial results for the quarter ended March 31, 2026 after the close of the U.S. market on Tuesday, May 5, 2026.

Management will hold a conference call and webcast for investors at 2:00 p.m. PT (5:00 p.m. ET). The conference call access number for U.S. participants is 866-580-3963, and the conference call access number for participants outside the U.S. is +1 786-697-3501. The conference ID number for both access numbers is 3731653. Additionally, interested parties can listen to a live webcast of the call from the "Investor Relations" section of SuRo Capital’s website at www.surocap.com. An archived replay of the webcast will also be available for 12 months following the live presentation.

A replay of the conference call may be accessed until 5:00 p.m. PT (8:00 p.m. ET) on May 12, 2026 by dialing 866-583-1035 (U.S.) or +44 (0) 20 3451 9993 (International) and using conference ID number 3731653.

About SuRo Capital Corp.

SuRo Capital Corp. (Nasdaq: SSSS) is a publicly traded investment fund that seeks to invest in high-growth, venture-backed private companies. The fund seeks to create a portfolio of high-growth emerging private companies via a repeatable and disciplined investment approach, as well as to provide investors with access to such companies through its publicly traded common stock. Since inception, SuRo Capital has served as the public's gateway to venture capital, offering unique access to some of the world’s most innovative and sought-after private companies before they become publicly traded. SuRo Capital’s diverse portfolio encompasses high-growth sectors including AI infrastructure, emerging consumer brands, and cutting-edge software solutions for both consumer and enterprise markets, among others. SuRo Capital is headquartered in New York, NY and has an office in San Francisco, CA. Connect with the Company on X, LinkedIn, and at www.surocap.com.

Contact
SuRo Capital Corp.
(212) 931-6331
[email protected]


Risks

  • Market volatility and economic uncertainty could impact the valuation and performance of venture-backed private companies in SuRo Capital's portfolio.
  • The timing and success of portfolio companies' eventual public offerings or exits are uncertain, affecting future returns.
  • Exposure to emerging technology sectors such as AI infrastructure may entail technological and regulatory risks.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026